Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Investigated for use/treatment in myocardial infarction.
- Mechanism
- Curator reviewed
Lanoteplase is a second generation derivative of alteplase, and a third generation recombinant plasminogen activator made from a deletion and point mutant of tissue type-plasminogen activator (t-PA). Lanoteplase has a longer half life than alteplase. Lanoteplase is a serine protease that binds to fibrin in a thrombus (blood clot)and cleaves the Arg-Val bond in plasminogen, producing active plasmin. Plasmin is an enzyme that degrades plasma proteins such as fibrin clots to clear blocked blood vessels that cause myocardial infarction (heart attack) or stroke.
- Primary indication
- Investigated for use/treatment in myocardial infarction.Curator reviewed
- Code names
- BMS-200980 · SUN-9216
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with Lanoteplase, and which of those have an active Phase 3 trial?